

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**VIVA BIOTECH HOLDINGS**

**维亚生物科技控股集团**

*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

**COMPLETION OF VERY SUBSTANTIAL ACQUISITION  
IN RELATION TO 80% OF THE EQUITY INTEREST OF  
LANGHUA PHARMACEUTICAL**

References are made to the announcements dated August 9, 2020, September 11, 2020 and September 29, 2020, the circular dated October 16, 2020 (the “**Circular**”) and the poll results announcement dated November 9, 2020 of Viva Biotech Holdings (the “**Company**”) in relation to the very substantial acquisition of 80% of the equity interest in Langhua Pharmaceutical. Unless otherwise defined, capitalized terms used herein shall have the same meaning as those defined in the Circular.

The Board is pleased to announce that all the conditions precedent set out in the Share Purchase Agreement have been fulfilled and the Completion took place on November 12, 2020. Upon Completion, Langhua Pharmaceutical becomes a non-wholly owned subsidiary of the Company and its financial results, assets and liabilities will be consolidated into the accounts of the Group.

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**

*Chairman and Chief Executive Officer*

Hong Kong, November 13, 2020

*As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; a Non-executive Director, namely, Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*